CDK9 and acute myeloid leukemia: A phase 1 trial of AZD4573 [a CDK9 inhibitor for which preclinical data have been presented (175, 176) but have not yet been published] in relapsed or refractory AML and other hematologic malignancies (NCT03263637) was initiated in October 2017.